Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Aug 3;210(3):435–450. doi: 10.1083/jcb.201501002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 8. — Concurrent deletion of TFEB, MITF, and TFE3 results in lysosomal and mitophagy defects. (A, left) WT and TFEB/MITF/TFE3 TKO (TKO) cells stably expressing YFP-Parkin and mt-mKeima were treated with DMSO or O/A for 18 h and subjected to FACS analysis. Plots are representative of n = 4 experiments. (A, right) Proportion of cells in the lower gate in left panels after 18-h O/A treatment. Data are means ± SD. **, P < 0.01. (B) WT and TKO cells stably expressing mCherry-Parkin were treated with DMSO or O/A for 18 h, fixed, immunostained for p62 and LAMP2, and analyzed by immunofluorescence. Left-most panels are enlarged versions of boxed regions in LAMP2 panels. Images are representative of n = 3 experiments where z stacks of five fields per condition (40–50 cells/field) per experiment were collected. Bars, 10 µm. (C and D) WT and TKO cells lacking endogenous Parkin (C) or stably expressing mCherry-Parkin (D) were treated with DMSO or O/A for 18 h, lysed, and immunoblotted. Three independent experiments (a–c) are shown.